Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01913600 · ClinicalTrials.gov registry record · NA
Resolute Integrity US Extended Length Sub-Study(RI US XL)
A NA study, sponsored by Medtronic Vascular.
- Completed
- Registry status
- NA
- Development phase
- 56
- Enrollment target
NCT01913600 is a NA study that has completed, run by Medtronic Vascular. The registered enrollment target is 56 participants.
The verdict
NCT01913600, a NA study, has completed, sponsored by Medtronic Vascular.
- COMPLETED
- Registry status
- NA
- Development phase
- 56 participants
- Enrollment target
Study Summary
Prospective, multi-center, non-randomized, single-arm, open-label study to assess the safety and efficacy of the Resolute Integrity Stent for the treatment of de novo lesions in native coronary arteries with a reference vessel diameter (RVD) of 2.25 mm to 4.2 mm in patients who receive extended length stents (34 mm or 38 mm) referred to as the Extended Length Study.
Interventions
- DEVICE Resolute Integrity Stent
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2013-07 |
| Est. Completion | 2018-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01913600
The ClinicalTrials.gov registry entry for NCT01913600 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medtronic Vascular, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Resolute Integrity Stent is the first listed.
NCT01913600 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01913600 about?
NCT01913600 is a clinical study titled "Resolute Integrity US Extended Length Sub-Study(RI US XL)". Prospective, multi-center, non-randomized, single-arm, open-label study to assess the safety and efficacy of the Resolute Integrity Stent for the treatment of de novo lesions in native coronary arteries with a reference vessel diameter (RVD) of 2.25 mm to 4.2 mm in patients who receive extended leng...
What is the current status of trial NCT01913600?
This trial is currently completed. It is a NA study. The enrollment target is 56 participants. The study started on 2013-07. Estimated completion is 2018-12.
What interventions are being tested in trial NCT01913600?
The interventions under investigation include: Resolute Integrity Stent (DEVICE).
Who is sponsoring clinical trial NCT01913600?
This trial is sponsored by Medtronic Vascular, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.